GlassScriptPhysician profile
Visali Kodali
NPI 1851625164
$1,419.96
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2022: $644 · 2023: $314 · 2024: $42.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $356.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $247.63 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Janssen Pharmaceuticals, INC | $134.02 | 2019-2023 | Xarelto |
| Pfizer INC. | $132.49 | 2019-2023 | |
| Amgen INC. | $108.48 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.24 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $92.19 | 2019-2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $75.78 | 2019-2023 | |
| Biotronik INC. | $67.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $53.50 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $53.33 | 2022-2023 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $51.58 | 2023 | |
| Boston Scientific Corporation | $39.69 | 2022-2023 | Watchman Flx |
| Cvrx, INC. | $36.72 | 2022-2024 | Barostim Neo System |
| Elutia, INC. | $30.81 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $26.50 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $25.95 | 2022 | |
| Medtronic Vascular, INC. | $21.88 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $21.30 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $20.72 | 2023 | Nexletol |
| Impulse Dynamics (USA) INC. | $18.45 | 2022 | |
| Gilead Sciences, INC. | $18.12 | 2019 | |
| Novo Nordisk INC | $17.29 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $15.65 | 2023 | Inpefa |
| Medtronic, INC. | $11.77 | 2022 | |
| G Medical Diagnostic Services, INC. | $6.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Visali Kodali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.